For the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days
SANCUSO helps prevent chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who are mechanically compromised and/or who may be unable to take or retain oral antiemetics1,2,a,b
Patients receiving oral chemotherapy3
Patients with breast cancer3
Patients with previous breakthrough symptoms3
Patients who are forgetful4
This offer is not valid for prescriptions under Medicare (including Medicare Advantage, Part A, B, and D plans), Medicaid, VA, DOD, TRICARE, CHAMPUS, or other federal or state healthcare programs. This offer is not valid for prescriptions in Massachusetts or in any other state that does not permit co-pay reimbursement consistent with this program. Patients without commercial insurance are not eligible for this program. Unless otherwise indicated on the submission form, SANCUSO will be dispensed through select ASPN pharmacies in the ASPN network. Cumberland Pharmaceuticals Inc. reserves the right to cancel or modify the program at any time.
You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.
Stay informedSancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
